Nav: Home

Tasmanian devil research could help tackle immunotherapy resistance

September 26, 2019

A cluster of interacting proteins that are active in both human cancers and Tasmanian devil facial tumours, may give clues to how cancers evade the immune system, according to a study part-funded by Cancer Research UK and published in Cancer Cell today (Thursday)*.

This early work in cells could one day guide us towards new drug combinations that improve the effectiveness of immunotherapy treatments.

Researchers at the Peter MacCallum Cancer Centre and University of Melbourne, Australia, in collaboration with scientists in the UK, investigated the reasons why some cancer cells lose proteins from their surface, allowing them to hide from the immune system.

They found that when a protein complex called PRC2, is over active, cancer cells lose the ability to present a protein called MHC class I. Expression of MHC class I is essential for tumours to be recognised by the body's immune defences.** Interestingly, it appears that loss of MHC class I in Tasmanian devil tumour cells may be due to the same process.

Dr Marian Burr, lead author of the study said: "We think this could contribute to some cancers in people becoming resistant to immunotherapies, and why cancer cells are not destroyed when transmitted between Tasmanian devils."

Devil facial tumour (DFT) is a common type of cancer in Tasmanian devils that is almost always lethal. Unlike any cancer in people, this unique disease is contagious and can be transmitted between individuals when the devils bite each other's faces, either as part of their mating ritual or to protect their territory.***

While humans cannot pass cancer to other people, the researchers suggest this newly observed similarity in the way cancer cells evade the immune system may explain why some cancers respond less well to immunotherapy than others.

The research team have suggested that a class of drug called EZH2 inhibitors, which are already in clinical trials for lymphoma and other cancers, could be an effective treatment for overcoming immune evasion.

When they blocked the activity of EZH2 in cells in the lab, MHC class I molecules were restored on the cell surface, allowing the cancer cells to be targeted by the immune system once more.****

"EZH2 inhibitors are showing promising results in clinical trials," added Prof Mark Dawson, from the Peter MacCallum Cancer Centre, who is senior author on the study. "So we want to investigate whether they can be combined with immunotherapy treatments, and if they could help patients who don't respond to immunotherapies alone. This approach may be particularly beneficial for cancers such as small cell lung cancer that have low expression of MHC class I."

Dr Rachel Shaw from Cancer Research UK said: "It's interesting to see how our understanding of cancers in other species might help us tackle some of the biggest problems in human cancer research.

"Immunotherapy treatments have shown great promise for certain patients, but some people will become resistant - and for others, these types of treatment don't work at all. Understanding why is a crucial step towards improving how we use the immune system to treat cancer.

"We hope this early research will lead to clinical trials testing more effective forms of immunotherapy, which could help more people survive cancer in the future."
-end-


Cancer Research UK

Related Science Articles:

75 science societies urge the education department to base Title IX sexual harassment regulations on evidence and science
The American Educational Research Association (AERA) and the American Association for the Advancement of Science (AAAS) today led 75 scientific societies in submitting comments on the US Department of Education's proposed changes to Title IX regulations.
Science/Science Careers' survey ranks top biotech, biopharma, and pharma employers
The Science and Science Careers' 2018 annual Top Employers Survey polled employees in the biotechnology, biopharmaceutical, pharmaceutical, and related industries to determine the 20 best employers in these industries as well as their driving characteristics.
Science in the palm of your hand: How citizen science transforms passive learners
Citizen science projects can engage even children who previously were not interested in science.
Applied science may yield more translational research publications than basic science
While translational research can happen at any stage of the research process, a recent investigation of behavioral and social science research awards granted by the NIH between 2008 and 2014 revealed that applied science yielded a higher volume of translational research publications than basic science, according to a study published May 9, 2018 in the open-access journal PLOS ONE by Xueying Han from the Science and Technology Policy Institute, USA, and colleagues.
Prominent academics, including Salk's Thomas Albright, call for more science in forensic science
Six scientists who recently served on the National Commission on Forensic Science are calling on the scientific community at large to advocate for increased research and financial support of forensic science as well as the introduction of empirical testing requirements to ensure the validity of outcomes.
World Science Forum 2017 Jordan issues Science for Peace Declaration
On behalf of the coordinating organizations responsible for delivering the World Science Forum Jordan, the concluding Science for Peace Declaration issued at the Dead Sea represents a global call for action to science and society to build a future that promises greater equality, security and opportunity for all, and in which science plays an increasingly prominent role as an enabler of fair and sustainable development.
PETA science group promotes animal-free science at society of toxicology conference
The PETA International Science Consortium Ltd. is presenting two posters on animal-free methods for testing inhalation toxicity at the 56th annual Society of Toxicology (SOT) meeting March 12 to 16, 2017, in Baltimore, Maryland.
Citizen Science in the Digital Age: Rhetoric, Science and Public Engagement
James Wynn's timely investigation highlights scientific studies grounded in publicly gathered data and probes the rhetoric these studies employ.
Science/Science Careers' survey ranks top biotech, pharma, and biopharma employers
The Science and Science Careers' 2016 annual Top Employers Survey polled employees in the biotechnology, biopharmaceutical, pharmaceutical, and related industries to determine the 20 best employers in these industries as well as their driving characteristics.
Three natural science professors win TJ Park Science Fellowship
Professor Jung-Min Kee (Department of Chemistry, UNIST), Professor Kyudong Choi (Department of Mathematical Sciences, UNIST), and Professor Kwanpyo Kim (Department of Physics, UNIST) are the recipients of the Cheong-Am (TJ Park) Science Fellowship of the year 2016.
More Science News and Science Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Uncharted
There's so much we've yet to explore–from outer space to the deep ocean to our own brains. This hour, Manoush goes on a journey through those uncharted places, led by TED Science Curator David Biello.
Now Playing: Science for the People

#555 Coronavirus
It's everywhere, and it felt disingenuous for us here at Science for the People to avoid it, so here is our episode on Coronavirus. It's ok to give this one a skip if this isn't what you want to listen to right now. Check out the links below for other great podcasts mentioned in the intro. Host Rachelle Saunders gets us up to date on what the Coronavirus is, how it spreads, and what we know and don't know with Dr Jason Kindrachuk, Assistant Professor in the Department of Medical Microbiology and infectious diseases at the University of Manitoba. And...
Now Playing: Radiolab

Dispatch 1: Numbers
In a recent Radiolab group huddle, with coronavirus unraveling around us, the team found themselves grappling with all the numbers connected to COVID-19. Our new found 6 foot bubbles of personal space. Three percent mortality rate (or 1, or 2, or 4). 7,000 cases (now, much much more). So in the wake of that meeting, we reflect on the onslaught of numbers - what they reveal, and what they hide.  Support Radiolab today at Radiolab.org/donate.